has increased its equity stake in Yapan Bio to 74.00% from 33.33% for ₹76 crore, utilizing a call option to elevate Yapan Bio's status from an associate company to a subsidiary. This acquisition integrates Yapan's process development and Phase I/II GMP manufacturing capabilities for vaccines and biologics into Piramal's contract development and manufacturing (CDMO) vertical. By transforming Yapan Bio from a strategic minority investment into a subsidiary, Piramal Pharma can now fully integrate advanced biologics and vaccine development capabilities into its broader CDMO platform, Piramal Pharma Solutions. This allows the company to capture higher margin services in high-growth segments such as gene therapy and complex biologics, which were previously limited under the associate structure. The transition of Yapan Bio into a consolidated subsidiary marks a key execution milestone in Piramal Pharma's long-term strategy to expand its high-value biologics CDMO services, positioning it well to capture global outsourced biopharma demand. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.

#StockInNews#Miscellaneous

657 likes·71 comments